Business Wire

PA-SYNERGIS-SOFTWARE

9.3.2022 15:24:09 CET | Business Wire | Press release

Share
Synergis Software Rebrands Adept Engineering Document Management with Increased Investments to Accelerate Growth

Synergis Software, a global leader in engineering document management and workflow solutions, today announced a rebrand and new website in synchrony with major investments in product development and customer success. These initiatives will fast track the company’s delivery of superior products and services to their global customer base.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005289/en/

“We see so much opportunity to have a positive impact on the customers we serve, which is why we’re making major investments in the company," states Scott Lamond, vice president of marketing at Synergis Software. "We want our brand to align with our mission of transforming the way our customers work— providing greater clarity, control, alignment, and harmony—so they can accelerate engineering projects, streamline operations, reduce risk, and lower costs." Watch the rebrand video .

The Adept platform is used by 120,000 users worldwide, including Dow Chemical, Con Edison, Amazon, Merck, and General Mills, and is managing over $1B in digital assets.

“Adept manages billions of dollars of digital assets containing priceless Dow intellectual property, with thousands of users across several dozen global sites," says Teresa Yang, Product Manager, Document Management, Dow Chemical.

Synergis is committed to accelerating the company’s growth and elevating the value delivered to customers with significant investments in their products.

“We’re tripling the size of our software development organization. By the end of 2022, our team will have grown by 218% in just two years,” explains Todd Cummings, vice president of research and development at Synergis. “The added positions include developers, QA staff, product managers, DevOps, SCRUM Masters, and User Experience professionals. Key leaderships roles are in place to help us refine the processes, tools, and methods we use to develop and deliver more value, faster.”

Synergis is investing substantially in the Adept platform, including the upcoming release of a new, integrated visualization solution for 2D and 3D engineering designs and other document types, along with major new feature enhancements and support for new versions of mainstream CAD systems. A new Cloud version of Adept is underway for customers who want to lower their IT costs and simplify deployment and upgrades.

“We’ll continue to build on Synergis Software’s legacy of extraordinary, love-based service and treating customers like family," adds Lamond. Toward that end, Synergis is expanding its customer success team, developing an online “Adept Academy”, and launching three new services options, including:

  • Ongoing Technical Consulting - Customers can work one-on-one with a dedicated Adept technical consultant on a regular basis to improve their Adept environment, streamline processes, remove roadblocks, and increase the value of Adept to their organization. Synergis experts will provide strategic and technical guidance on nearly any type of project to help customers reach their goals.
  • Remote Adept Administration - Customers can outsource the day-to-day application management and administration of Adept to our experienced technical staff to keep their resources focused on what’s most important to their business. Our managed services will help keep our customer’s Adept environment optimized and lower operating costs.
  • Adept Server Hosting - Customers can outsource the hosting of their entire Adept Server environment to free up IT resources, lower operating costs, and improve security.

Synergis Software’s focus and investments in service and support will help maintain their strong leadership position in the market, as validated in the rankings on the G2 software review site.

“We couldn’t have arrived at this moment without 30 years of thoughtful, collaborative, and visionary support from our customer community and the individuals who have shaped us,” added Lamond. “We’re grateful for their influence as we build our future together.”

About Synergis Software

Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects enterprise applications so critical data and business processes can flow seamlessly across the entire IT infrastructure.

Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, the company's commitment to its customers is unwavering.

Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded. For more information, visit SynergisSoftware.com.

Link:

ClickThru

Social Media:

https://www.facebook.com/synergissoftware/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye